Clinical, Behavioral, and Physiological Studies of Open- and Closed-loop Platforms: Toward Personalized, Fully Automated, Accessible Systems (R01 Clinical Trial Required)

US Dept. of Health & Human Services: National Institutes of Health (NIH)

Note: This grant page has been archived and is very likely out of date.
Crystal ball icon
Predicted Deadline
The next cycle for this opportunity is predicted based on past data. If you save this grant, we’ll notify you if there are any changes.

Predicted deadline: The deadline for this grant has passed

Grant amount: Up to US $2,500,000

Fields of work: Diabetes Endocrine & Metabolic Diseases

Applicant type: Government Entity, Indigenous Group, Nonprofit, For-Profit Business

Funding uses: Research

Location of project: Anywhere in the world

Location of residency: Anywhere in the world

Overview:

The purpose of this funding opportunity announcement (FOA) is to promote clinical research using current and emerging technologies to address barriers that limit progress toward physiological pancreatic hormone replacement open- and closed-loop systems. It will support research to:

  • test and improve the safety, reliability, and clinical efficacy of these technologies;
  • address behavioral/psychosocial factors that play a role in the usability and acceptance of these systems and validation of measures that may be used as outcomes for the demonstration of efficacy and benefit;
  • test these technologies in subpopulations of patients not usually included in clinical trials who may benefit the most from their use;
  • test these technologies in individuals who are underserved or in low income and/or racial and ethnic minority groups, and better understand disparities in the use and adoption of these systems; and 
  • use the technologies as tools to advance understanding of glucose regulation and its pathophysiology in patients with type 1 diabetes (T1D) including counter-regulation and impaired awareness of hypoglycemia.

Research goals include improved metabolic control with decreased glycemic excursions, prevention of acute and chronic complications, and improved quality of life in patients with diabetes and their caregivers. Only human studies will be considered responsive to this FOA, applications involving animal or in vitro studies are not responsive to this FOA.

We've imported the main document for this grant to give you an overview. You can learn more about this opportunity by visiting the funder's website.

US Dept. of Health & Human Services: National Institutes of Health (NIH)
FUNDER

Your history with this funder
0
SAVED OPPORTUNITIES
No saved opportunities from this funder yet
FUNDER NOTES
Save this opportunity to add notes...
CONTACTS
Save this opportunity to add contacts...

Other Funding Opportunities from Us Dept. Of Health & Human Services: National Institutes Of Health (Nih)

Forecasted Funding Opportunities from Us Dept. Of Health & Human Services: National Institutes Of Health (Nih) help icon

Don't miss out on other good fit funders!

Get personalized grant recommendations, tracking and more by creating a free 14-day account.

No credit card required.
instrumentl testimonial face

"Winning 30% more grants thanks to Instrumentl was a huge morale boost. My confidence continues to grow."

Linda Rucker, Grant Writer

This page was last reviewed May 09, 2023 and last updated May 09, 2023